| ID | 1226 |
| Name of the vaccine | GBS Trivalent vaccine |
| Microbe | Bacteria |
| Disease name | Streptococcal Disease, Group B |
| Name of bacteria | Streptococcus agalactiae (Group B Streptococcus) |
| Type of vaccine | Conjugate |
| Nucleic acid content | Circular DNA |
| Age | 18 to 40 years (non-pregnant women) |
| Description of the vaccine | Polysaccharide capsules from serotypes IA, IBM, and III of the Group B Streptococcus. |
| Name of the manufacturer | GlaxoSmithKline |
| Name of the manufacturing country | Belgium, Czechia, United States |
| Year of manufacture | 2015 |
| Clinical Phase status | Clinical - Phase 2 |
| Bacterial strain | Gram-positive coccus. |
| Efficacy | NA |
| Vaccine formulation | Liquid or lyophilized formulation |
| Dosage | Single dose |
| Mechanism of action | GBS serotype-specific antibodies. |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT02270944 |
| Reference | https://adisinsight.springer.com/drugs/800026395 |
| Other name | NA |
| Additional Links | NA
|